Spyre Therapeutics, Inc. short interest in 2024
In 2024, Spyre Therapeutics, Inc.'s disclosed short interest ran from 11.21% of shares outstanding on 15 May 2024 to 19.33% on 31 Dec 2024, a change of +8.12 percentage points. The year's high was 22.48% on 15 Jul 2024 and its low 11.21% on 15 May 2024, averaging 16.64% across 16 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 22.94 days on 31 Oct 2024. Full history: Spyre Therapeutics, Inc..
Cite this page
By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2024 in figures
- Start of year
- 11.21% (15 May 2024)
- End of year
- 19.33% (31 Dec 2024)
- Change
- +8.12 pp
- High
- 22.48% (15 Jul 2024)
- Low
- 11.21% (15 May 2024)
- Average
- 16.64%
- Highest days to cover
- 22.94 (31 Oct 2024)
- SEC filings marked
- 8
Every report in 2024
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 15 May 2024 | 11.21% | 14.53 | 10-K filed, results (8-K), 10-Q filed, results (8-K) |
| 31 May 2024 | 11.36% | 15.49 | |
| 14 Jun 2024 | 12.02% | 10.63 | |
| 28 Jun 2024 | 19.34% | 4.30 | |
| 15 Jul 2024 | 22.48% | 14.82 | |
| 31 Jul 2024 | 19.39% | 17.75 | |
| 15 Aug 2024 | 15.83% | 20.78 | 10-Q filed, results (8-K) |
| 30 Aug 2024 | 16.66% | 20.02 | |
| 13 Sep 2024 | 17.18% | 21.16 | |
| 30 Sep 2024 | 17.02% | 10.43 | |
| 15 Oct 2024 | 16.56% | 22.05 | |
| 31 Oct 2024 | 16.24% | 22.94 | |
| 15 Nov 2024 | 15.63% | 14.83 | 10-Q filed, results (8-K) |
| 29 Nov 2024 | 17.23% | 9.57 | |
| 13 Dec 2024 | 18.71% | 19.68 | |
| 31 Dec 2024 | 19.33% | 19.88 |
See also: Spyre Therapeutics, Inc.'s full history · most shorted US stocks of 2024 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.